2020-03-12
Visited : 2778
Cambridge Raman Imaging Ltd. – the portfolio firm of Frontier IP Group PLC – has recently won €140,000 in EU funding to speed up the development of its new scanning microscope that employs graphene to modulate ultra-short pulses of light for tracking cancer cells.
Frontier IP Group PLC’s portfolio firm, Cambridge Raman Imaging Limited (CRIL), has been awarded €140,000 (£116,380) in EU funding to accelerate development of its graphene-enabled scanning microscope.
CRIL, which was spun out from the University of Cambridge and Italian university Politecnico di Milano in 2018, is developing a microscope which uses graphene to modulate ultra-short pulses of light to diagnose and track cancer tumours.
The technology will target real-time digital images of fresh tissue samples to show the extent of tumours, their response to drug treatments and to allow surgeons to see if a cancer has been completely removed.
Frontier, which owns 33.3% of the firm, said CRIL’s technology will be compact enough to be used in operating theatres, reducing the time needed for analysis which currently requires samples to be extracted from a patient and then taken to a lab.
Potential future applications include scanning bodily fluids for pathogens and tumour cells, as well as in imaging semiconductors or proteins. The grant is funded by the EU’s graphene flagship, an initiative to help develop uses for graphene in society from academic research.
"Cambridge Raman Imaging is our first spin out to develop a graphene-based technology. Although the first applications are in healthcare, we believe there could be broader applications in other industries”, said Frontier’s chief executive Neil Crabb.
“We're delighted the EU Graphene Flagship recognises the potential of the technology with the grant award to accelerate its development", he added.
Read the original article on Proactive Investors.